To include your compound in the COVID-19 Resource Center, submit it here.

Attune raises $23M, reports safety data for angioedema candidate

Rare diseases company Attune Pharmaceuticals (New York, N.Y.) raised $23 million in a series B round

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE